Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia

Molecular Pharmacology

Volumn 81, Issue 1, 2012, Pages 31-40

  Guise, Christopher P ^a,b   Abbattista, Maria R ^a   Tipparaju, Smitha R ^a   Lambie, Neil K ^c,d   Su, Jiechuang ^a   Li, Dan ^a   Wilson, William R ^a,b   Dachs, Gabi U ^b,d   Patterson, Adam V ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CYTOCHROME P450 REDUCTASE; DIFLAVIN OXIDOREDUCTASE; DIPHENYLIODONIUM SALT; FLAVOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE 2A; METHIONINE SYNTHASE REDUCTASE; NOVEL DIFLAVIN OXIDOREDUCTASE 1; OXIDOREDUCTASE; PR 104A; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; FLAVINS; FLAVOPROTEINS; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROGEN MUSTARD COMPOUNDS; OXIDATION-REDUCTION; OXIDOREDUCTASES; PRODRUGS;

EID: 84455170365     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.073759     Document Type: Article

References (40)

1. Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, and Workman P (2001) Involvement of NADPH:cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62:461-468.
2. Begleiter A, Leith MK, Patel D, and Hasinoff BB (2007) Role of NADPH cytochrome P450 reductase in activation of RH1. Cancer Chemother Pharmacol 60:713-723. (Pubitemid 47247283)
3. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, and Rimm D (2010) Antibody validation [published erratum appears in Biotechniques 48:351, 2010]. Biotechniques 48:197-209.
4. Chandor A, Dijols S, Ramassamy B, Frapart Y, Mansuy D, Stuehr D, Helsby N, and Boucher JL (2008) Metabolic activation of the antitumor drug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. Chem Res Toxicol 21:836-843. (Pubitemid 351644561)
5. Chen Y and Hu L (2009) Design of anticancer prodrugs for reductive activation. Med Res Rev 29:29-64.
6. Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL, and Stratford IJ (2003) Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 63:1248-1255. (Pubitemid 36627219)
7. Dachs GU, Kano M, Volkova E, Morrin HR, Davey VC, Harris GC, Cheale M, Frampton C, Currie MJ, Wells JE, et al. (2010) A profile of prognostic and molecular factors in European and Māori breast cancer patients. BMC Cancer 10:543.
8. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID, Telfer C, Melvin WT, and Murray GI (2005) Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 11:7369-7375. (Pubitemid 41507696)
9. Evans SM, Schrlau AE, Chalian AA, Zhang P, and Koch CJ (2006) Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J Invest Dermatol 126:2596-2606. (Pubitemid 44764043)
10. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88:259-269.
11. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, and Au JL (2001) Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors. Clin Cancer Res 7:1313-1319. (Pubitemid 32708686)
12. Gu Y, Guise CP, Patel K, Abbattista MR, Li J, Lie J, Sun X, Atwell GJ, Boyd M, Patterson AV, et al. (2011a) Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol 67:543-555.
13. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, and Wilson WR (2009) Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 8:1714-1723.
14. Gu Y, Tingle MD, and Wilson WR (2011b) Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy. J Pharmacol Exp Ther 337:692-702.
15. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70:1573-1584.
16. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, and Patterson AV (2007) Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74:810-820.
17. Hall PM, Stupans I, Burgess W, Birkett DJ, and McManus ME (1989) Immunohistochemical Localization of NADPH-Cytochrome P450 Reductase in Human Tissues. Carcinogenesis 10:521-530. (Pubitemid 19089919)
18. Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, et al. (2010) Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 16:4946-4957.
19. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, et al. (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905-919. (Pubitemid 32221783)
20. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, and Wilson WR (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791-801.
21. Kaluz S, Kaluzová M, Liao SY, Lerman M, and Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795:162-172.
22. Koumenis C and Wouters BG (2006) "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 4:423-436. (Pubitemid 44197038)
23. Louërat-Oriou B, Perret A, and Pompon D (1998) Differential redox and electrontransfer properties of purified yeast, plant and human NADPH-cytochrome P-450 reductases highly modulate cytochrome P-450 activities. Eur J Biochem 258:1040-1049.
24. Mendes AF, Carvalho AP, Caramona MM, and Lopes MC (2001) Diphenyleneiodonium inhibits NF-≲καππα∀B activation and INOS expression induced by IL-1β: involvement of reactive oxygen species. Mediators Inflamm 10:209-215.
25. Murataliev MB, Feyereisen R, and Walker FA (2004). Electron transfer by diflavin reductases. Biochim Biophys Acta 1698:1-26. (Pubitemid 38446896)
26. O'Donnell VB, Smith GC, and Jones OT (1994) Involvement of phenyl radicals in iodonium inhibition of flavoenzymes. Mol Pharmacol 46:778-785.
27. Olteanu H and Banerjee R (2003) Redundancy in the pathway for redox regulation of mammalian methionine synthase: reductive activation by the dual flavoprotein, novel reductase 1. J Biol Chem 278:38310-38314. (Pubitemid 37221722)
28. Papadopoulou MV, Ji M, Rao MK, and Bloomer WD (2003) Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14:21-29. (Pubitemid 38166341)
29. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13:3922-3932. (Pubitemid 47037600)
30. Patterson AV, Saunders MP, Chinje EC, Patterson LH, and Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 13:541-573.
31. Patterson LH and McKeown SR (2000) AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83:1589-1593. (Pubitemid 32001698)
32. Philip PA, Kaklamanis L, Ryley N, Stratford I, Wolf R, Harris A, and Carmichael J (1994) Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man. Int J Radiat Oncol Biol Phys 29:277-283. (Pubitemid 24166532)
33. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, et al. (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995.
34. Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, and Wilson WR (2009) DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. Cancer Res 69:3884-3891.
35. Ticconi C, Zicari A, Belmonte A, Realacci M, Rao ChV, and Piccione E (2007) Pregnancy-promoting actions of HCG in human myometrium and fetal membranes. Placenta 28 (Suppl A):S137-S143.
36. van den Beucken T, Koritzinsky M, Niessen H, Dubois L, Savelkouls K, Mujcic H, Jutten B, Kopacek J, Pastorekova S, van der Kogel AJ, et al. (2009) Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem 284:24204-24212.
37. Vaupel P and Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239. (Pubitemid 47101660)
38. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, et al. (2011) Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 17:2997-3004.
39. Wilson WR and Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410.
40. Workman P and Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12:73-82. (Pubitemid 23220673)